Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:CBAY NASDAQ:ONCT NASDAQ:PRQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$3.17-3.4%$3.32$2.71▼$4.73$607.14M1.2956,829 shs1.12 million shsCBAYCymaBay Therapeutics$32.48$32.44$7.26▼$32.50$3.73B0.324.11 million shs73 shsONCTOncternal Therapeutics$0.53$0.53$0.53▼$7.77$1.56M1.1893,010 shsN/APRQRProQR Therapeutics$2.32-1.7%$1.86$1.07▼$4.62$244.09M0.36661,984 shs186,473 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma0.00%-2.01%-11.45%+0.96%-7.04%CBAYCymaBay Therapeutics0.00%0.00%0.00%0.00%0.00%ONCTOncternal Therapeutics0.00%0.00%0.00%0.00%-92.81%PRQRProQR Therapeutics0.00%+8.26%+19.59%+107.14%+35.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABUSArbutus Biopharma2.1391 of 5 stars3.50.00.00.02.72.50.6CBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APRQRProQR Therapeutics2.5398 of 5 stars3.65.00.00.02.60.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 3.00Buy$5.5073.50% UpsideCBAYCymaBay Therapeutics 0.00N/AN/AN/AONCTOncternal Therapeutics 2.25Hold$10.001,798.97% UpsidePRQRProQR Therapeutics 3.13Buy$8.00244.83% UpsideCurrent Analyst Ratings BreakdownLatest ABUS, CBAY, ONCT, and PRQR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/11/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/27/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$8.006/27/2025PRQRProQR TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$8.005/13/2025PRQRProQR TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$15.00 ➝ $9.004/29/2025PRQRProQR TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$8.004/29/2025PRQRProQR TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$5.00(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$6.40M94.82N/AN/A$0.51 per share6.22CBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59ONCTOncternal Therapeutics$790K1.97N/AN/A$10.19 per share0.05PRQRProQR Therapeutics$18.97M12.86N/AN/A$0.91 per share2.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$69.92M-$0.41N/AN/AN/A-1,196.64%-75.51%-55.81%8/7/2025 (Estimated)CBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%N/AONCTOncternal Therapeutics-$39.48M-$11.69N/AN/AN/A-1,599.95%-177.58%-131.30%N/APRQRProQR Therapeutics-$30.04M-$0.35N/AN/AN/A-157.04%-53.49%-22.07%8/4/2025 (Estimated)Latest ABUS, CBAY, ONCT, and PRQR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ABUSArbutus Biopharma-$0.02N/AN/AN/AN/AN/A5/14/2025Q1 2025ABUSArbutus Biopharma-$0.09-$0.13-$0.04-$0.13$2.54 million$1.76 million5/8/2025Q1 2025PRQRProQR Therapeutics-$0.09-$0.1082-$0.0182-$0.11$4.90 million$4.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AONCTOncternal TherapeuticsN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus Biopharma0.046.016.01CBAYCymaBay TherapeuticsN/A10.9610.96ONCTOncternal TherapeuticsN/A2.392.39PRQRProQR TherapeuticsN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%CBAYCymaBay Therapeutics95.03%ONCTOncternal Therapeutics16.05%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma20.30%CBAYCymaBay Therapeutics7.00%ONCTOncternal Therapeutics11.20%PRQRProQR Therapeutics8.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90191.53 million152.65 millionOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableONCTOncternal Therapeutics302.96 million2.63 millionNo DataPRQRProQR Therapeutics180105.21 million96.38 millionOptionableABUS, CBAY, ONCT, and PRQR HeadlinesRecent News About These CompaniesProQR Therapeutics price target raised to $5 from $4 at Evercore ISIJuly 12 at 10:30 AM | msn.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces clinical hurdles - Investing.comJuly 8, 2025 | investing.comProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Here's WhyJuly 8, 2025 | marketbeat.comPRQR - ProQR Therapeutics NV Sustainability - MorningstarJuly 3, 2025 | morningstar.comMBrokerages Set ProQR Therapeutics N.V. (NASDAQ:PRQR) Target Price at $8.00July 3, 2025 | americanbankingnews.comPRQR - ProQR Therapeutics NV Key Metrics - MorningstarJuly 2, 2025 | morningstar.comMProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Buy" from BrokeragesJune 30, 2025 | marketbeat.comProQR Therapeutics NV (PRQR) Stock Forums - Investing.comJune 29, 2025 | investing.comProQR Therapeutics N.V. (PRQR) - Yahoo FinanceJune 29, 2025 | finance.yahoo.comProQR Therapeutics N.V.: ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPJune 27, 2025 | finanznachrichten.deProQR Therapeutics' (PRQR) Market Outperform Rating Reiterated at JMP SecuritiesJune 27, 2025 | marketbeat.comProQR Therapeutics (NASDAQ:PRQR) Receives "Overweight" Rating from Cantor FitzgeraldJune 27, 2025 | marketbeat.comProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCPJune 26, 2025 | globenewswire.comProQR Therapeutics Reports Q1 2025 Financial ResultsJune 2, 2025 | tipranks.comProQR Therapeutics’ SWOT analysis: RNA editing pioneer’s stock faces pivotal yearMay 24, 2025 | investing.comProQR Therapeutics (PRQR) Price Target Lowered by Oppenheimer | PRQR Stock NewsMay 13, 2025 | gurufocus.comProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES ConferencesMay 12, 2025 | globenewswire.comProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial PositionMay 10, 2025 | nasdaq.comProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deProQR Therapeutics N.V.: ProQR Announces First Quarter 2025 Operating and Financial ResultsMay 10, 2025 | finanznachrichten.deNew Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR)May 10, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABUS, CBAY, ONCT, and PRQR Company DescriptionsArbutus Biopharma NASDAQ:ABUS$3.17 -0.11 (-3.35%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$3.14 -0.03 (-0.95%) As of 07/11/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.CymaBay Therapeutics NASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Oncternal Therapeutics NASDAQ:ONCT$0.53 0.00 (0.00%) As of 04/29/2025Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California.ProQR Therapeutics NASDAQ:PRQR$2.32 -0.04 (-1.69%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.42 +0.10 (+4.31%) As of 07/11/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Conagra at Rock Bottom: 7% Yield & Turnaround Poised Delta Air Lines Could Reach New Highs in 2025—And Here’s Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.